No Solid Evidence, Only Hollow Argument for Universal Tumor Sequencing
- 1 June 2016
- journal article
- viewpoint
- Published by American Medical Association (AMA) in JAMA Oncology
- Vol. 2 (6), 717
- https://doi.org/10.1001/jamaoncol.2016.0075
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trialThe Lancet Oncology, 2015
- Molecular Profiling and Targeted Therapy for Advanced Thoracic Malignancies: A Biomarker-Derived, Multiarm, Multihistology Phase II Basket TrialJournal of Clinical Oncology, 2015
- Personalized Medicine for Patients with Advanced Cancer in the Phase I Program at MD Anderson: Validation and Landmark AnalysesClinical Cancer Research, 2014
- Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted DrugsJAMA, 2014
- PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies Harboring PIK3CA MutationsJournal of Clinical Oncology, 2012